Skip to main content
Back to all tickers

Medicus Pharma Ltd. (MDCX) stock forecast & analysis

0.1720

NasdaqCM · USD

Up: +0.0015, +0.9%

0.1751Up: +0.0031, +1.8%

1 analysis

Use Arrow keys to explore price history; Home and End jump to the oldest and newest points
Price history for MDCX.US from 08-06 13:00 to 09-04 23:59 with 1 analysis run marked; public runs are shown as stance-colored dots (Bullish, Bearish, or Neutral) and gated runs as a lock icon (sign in to read). Each marker is a link to sign in.BullishBearishNeutralLocked · sign in to read

Open
0.1622
Previous close
0.1705
Day range
0.1600 – 0.1830
52-week range
0.1510 – 3.05
Volume (shares)
14.84M
Net assets
Not available
Expense ratio
Not available
Shares outstanding
63.18M
P/E ratio
Not available
Dividend yield
Not available
Beta
-0.48
Market cap
10.87M
Market Scanner’s AI analysis of Medicus Pharma Ltd. (MDCX), updated September 2026: Medicus Pharma Ltd. (MDCX) faces sustained net losses and increasing debt, alongside bearish technical indicators.

Summary

Medicus Pharma Ltd. (MDCX) faces sustained net losses and increasing debt, alongside bearish technical indicators.

Recent analyses for MDCX indicate a challenging financial and technical landscape. The company has reported consistent net losses, with a significant increase in total debt noted in the latest reporting period. Technically, MDCX exhibits strong bearish momentum, with its stock price trading well below key moving averages and indicators suggesting oversold conditions.

MDCX news & sentiment

News coverage for MDCX was limited, with no specific actionable insights beyond a general mention in a list of active stocks. Broader healthcare sector news showed some positive sentiment and activity, influenced by a strong jobs report.

MDCX technical picture

Technical indicators for MDCX presented a bearish outlook, with the stock price closing significantly below its 50-day and 200-day simple moving averages, indicating a downtrend. Momentum indicators like RSI and MFI were in oversold territory, while the MACD showed a bearish signal, and the price was below the lower Bollinger Band.

Fundamentals

Medicus Pharma Ltd. (MDCX) has consistently reported net losses, with a significant increase in total debt noted in the latest reporting period. Shareholder equity turned negative, while cash levels provided a limited buffer.

Factors discussed — upside

  • RSI and MFI in oversold territory suggest potential for a bounce.

Factors discussed — risks

  • Consistent net losses reported across fiscal years and recent quarters.
  • Significant increase in total debt from March 31, 2026, to June 30, 2026.
  • Stock price significantly below 50-day and 200-day SMAs.
  • Negative shareholder equity as of December 31, 2025.
  • Strong bearish momentum indicated by price changes and MACD.
  • Financial performance
  • Technical indicators
  • Debt levels
  • Market sentiment

Summary updated .

MDCX technical indicators

Common technical indicators for MDCX, computed from its daily closing prices.

IndicatorValueReading
50-day simple moving average0.33Price below
10-day exponential moving average0.23Price below
Relative strength index (14-day)27.67Oversold
MACD line (12/26/9)-0.0312Below its signal line
Bollinger bands (20-day, 2σ)0.18 – 0.36Price below the lower band

Analyses

Recent MDCX.US analyses are locked — sign in to read them or generate a fresh one.

CaseDescriptionDate

Frequently asked questions

What is the bull case for Medicus Pharma Ltd.?
The analyses noted that the Relative Strength Index (RSI) and Money Flow Index (MFI) are in oversold territory, suggesting a potential for a bounce.
What are the risks for Medicus Pharma Ltd.?
The company has consistently reported net losses and experienced a significant increase in total debt. The stock price is trading below key moving averages, and shareholder equity has turned negative, indicating strong bearish momentum.
Is Medicus Pharma Ltd. bullish or bearish?
Recent AI analyses of Medicus Pharma Ltd. examined factors on both sides. Discussed upside: The analyses noted that the Relative Strength Index (RSI) and Money Flow Index (MFI) are in oversold territory, suggesting a potential for a bounce. Discussed risks: The company has consistently reported net losses and experienced a significant increase in total debt. The stock price is trading below key moving averages, and shareholder equity has turned negative, indicating strong bearish momentum. These are descriptive observations, not a recommendation.
What is the latest sentiment on Medicus Pharma Ltd.?
News coverage for MDCX was limited, with no specific actionable insights beyond a general mention in a list of active stocks. Broader healthcare sector news showed some positive sentiment and activity, influenced by a strong jobs report.

Bundles used
gemini-low-v2

Run a fresh MDCX.US analysis

Configure the ticker, model bundle and debate depth here — you only sign in at the end, and everything you picked comes with you.

Or sign in to read every MDCX.US report already in the library



Most analyzed tickers